{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:55:43Z","timestamp":1794308143739,"version":"4.9.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajogmfm.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics & Gynecology MFM"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ajogmf.2023.101245","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T03:14:00Z","timestamp":1701832440000},"page":"101245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Common teratogenic medication exposures\u2014a population-based study of pregnancies in the United States"],"prefix":"10.1016","volume":"6","author":[{"given":"Yanning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Smolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Nhu","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sarayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja A.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-5961","authenticated-orcid":false,"given":"Almut G.","family":"Winterstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajogmf.2023.101245_bib0001","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajog.2021.02.032","article-title":"Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration","volume":"225","author":"Wesley","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0003","unstructured":"US Food and Drug Administration. Pregnancy and lactation labeling (drugs) final rule. Available at:https:\/\/www.fda.gov\/drugs\/labeling-information-drug-products\/pregnancy-and-lactation-labeling-drugs-final-rule. Accessed November 23, 2022."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2022.01.004","article-title":"Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies","volume":"227","author":"Sarayani","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0005","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.1235","article-title":"Use of prescription medications with a potential for fetal harm among pregnant women","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0006","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/AOG.0000000000000982","article-title":"The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program","volume":"126","author":"Palmsten","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s40264-021-01113-8","article-title":"Validating claims-based algorithms determining pregnancy outcomes and gestational age using a linked claims-electronic medical record database","volume":"44","author":"Moll","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/EDE.0000000000001559","article-title":"Development and validation of algorithms to estimate live birth gestational age in Medicaid analytic eXtract data","volume":"34","author":"Zhu","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2022.10.005","article-title":"Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy","volume":"228","author":"Winterstein","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/pds.4794","article-title":"Identifying pregnancies in insurance claims data: methods and application to retinoid teratogenic surveillance","volume":"28","author":"MacDonald","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40264-023-01287-3","article-title":"Validation of an ICD-9-Based algorithm to identify stillbirth episodes from Medicaid claims data","volume":"46","author":"Nduaguba","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0012","doi-asserted-by":"crossref","first-page":"m1494","DOI":"10.1136\/bmj.m1494","article-title":"Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study","volume":"369","author":"Zhu","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0013","unstructured":"Centers for Disease Control and Prevention. National vital statistics system, natality, on CDC WONDER online database. Available at: https:\/\/wonder.cdc.gov\/natality.html. Accessed May 1, 2023"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0014","unstructured":"Centers for Disease Control and Prevention. Prenatal care characteristics, January\u2013April, provisional 2019 and 2020. 2023. Available at: https:\/\/www.cdc.gov\/nchs\/health_policy\/prenatal-covid.htm. Accessed November 1, 2023."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0015","unstructured":"Kaiser Family Foundation. Abortion in the U.S. dashboard. Available at:https:\/\/www.kff.org\/womens-health-policy\/dashboard\/abortion-in-the-u-s-dashboard\/. Accessed November 23, 2022."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0016","series-title":"StatPearls","article-title":"Uncomplicated urinary tract infection (nursing)","author":"Bono","year":"2023"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0017","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11908-015-0462-0","article-title":"Vulvovaginal candidiasis in pregnancy","volume":"17","author":"Aguin","year":"2015","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/bdra.23570","article-title":"Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011","volume":"106","author":"Ailes","year":"2016","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0019","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0021","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0002-9378(98)80028-8","article-title":"Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group","volume":"178","author":"Cotch","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/pds.5035","article-title":"Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: a study in the five Nordic countries, United States, and Australia","volume":"29","author":"Cohen","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0023","unstructured":"US Food and Drug Administration. Information for Healthcare Professionals: risk of neural tube birth defects following prenatal exposure to valproate. Available at:https:\/\/wayback.archive-it.org\/7993\/20170406045008\/https:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm192649.htm. Accessed November 23, 2022."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0024","unstructured":"US Food and Drug Administration. FDA drug safety communication: children born to mothers who took valproate products while pregnant may have impaired cognitive development. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-children-born-mothers-who-took-valproate-products-while-pregnant-may. Accessed November 23, 2022."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0025","unstructured":"US Food and Drug Administration. FDA drug safety communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-valproate-anti-seizure-products-contraindicated-migraine-prevention. Accessed November 23, 2022."},{"key":"10.1016\/j.ajogmf.2023.101245_bib0026","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/AOG.0000000000003828","article-title":"Gynecologic management of adolescents and young women with seizure disorders: ACOG committee opinion summary, Number 806","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0027","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0b013e3181a6b2f8","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0028","first-page":"1","article-title":"U.S. Medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/EDE.0000000000001302","article-title":"A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug-drug interactions","volume":"32","author":"Sarayani","year":"2021","journal-title":"Epidemiology"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0030","first-page":"e521","article-title":"2014 AHA\/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Nishimura","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0031","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"ACOG practice bulletin no. 196: Thromboembolism in pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0033","doi-asserted-by":"crossref","first-page":"585","DOI":"10.15585\/mmwr.mm7117a1","article-title":"Hypertensive disorders in pregnancy and mortality at delivery hospitalization - United States, 2017-2019","volume":"71","author":"Ford","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.10.878","article-title":"Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions","volume":"206","author":"Bateman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0035","article-title":"ACOG practice bulletin no. 203: chronic hypertension in pregnancy","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0036","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/HYP.0000000000000208","article-title":"Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association","volume":"79","author":"Garovic","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0038","series-title":"StatPearls","article-title":"Angiotensin II receptor blockers (ARB)","author":"Hill","year":"2023"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0039","series-title":"StatPearls","article-title":"ACE inhibitors","author":"Goyal","year":"2023"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.327.7421.955","article-title":"Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis","volume":"327","author":"Magee","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0041","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajog.2020.03.016","article-title":"Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis","volume":"223","author":"Bellos","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0042","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.111.00833","article-title":"The risk of congenital malformations associated with exposure to \u03b2-blockers early in pregnancy: a meta-analysis","volume":"62","author":"Yakoob","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0043","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamainternmed.2017.0608","article-title":"\u03b2-Blocker exposure in pregnancy and risk of fetal cardiac anomalies","volume":"177","author":"Duan","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0044","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/M18-0338","article-title":"\u03b2-Blocker use in pregnancy and the risk for congenital malformations: an International Cohort Study","volume":"169","author":"Bateman","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.119.12968","article-title":"Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010","volume":"74","author":"Ananth","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0047","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0048","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0049","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0050","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0051","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1331\/JAPhA.2011.11519","article-title":"APhA 2011 REMS white paper: summary of the REMS stakeholder meeting on improving program design and implementation","volume":"51","author":"Bough","year":"2011","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0052","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jac5.1373","article-title":"Medication access: policy and practice opportunities for pharmacists","volume":"4","author":"Sobeski","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0053","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/bmjqs-2019-010098","article-title":"Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate","volume":"29","author":"Sarayani","year":"2020","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004190","article-title":"Analysis of risk evaluation and mitigation strategies for teratogenic drugs: variation in primary and secondary prevention measures","volume":"20","author":"Brown","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.ajogmf.2023.101245_bib0055","unstructured":"Medicaid's role in financing maternity care. Medicad and CHIP Payment and Access Commission. Available at:https:\/\/www.macpac.gov\/wp-content\/uploads\/2020\/01\/Medicaid%E2%80%99s-Role-in-Financing-Maternity-Care.pdf. Accessed November 23, 2022."}],"container-title":["American Journal of Obstetrics & Gynecology MFM"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933323003877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933323003877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:54:03Z","timestamp":1762905243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589933323003877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2589933323003877"],"URL":"https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101245","relation":{},"ISSN":["2589-9333"],"issn-type":[{"value":"2589-9333","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common teratogenic medication exposures\u2014a population-based study of pregnancies in the United States","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics & Gynecology MFM","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101245"}}